We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Chn9.0
Chondroitin Research
Probably helpsHigh safety
46 peer-reviewed studies
What the evidence says
Probably helps
Chondroitin helped in about half (7/11) of the studies that measured an effect — promising, but not unanimous.
Most evidence is from high-quality meta-analyses and randomised trials published 2006–2026 with a typical study size of 166 participants.
Based on 46 studies · 18 meta-analyses · 12 RCTs · 73,337 total participants
Confidence
High
What the studies found
7helped2unclear2didn't help· 35 more without graded effect data
By outcome
Joint pain & arthritisImproved joint comfort and cartilage support within 8-12 weeks · 8-12 weeks
Probably helps41 studies
Safety profile
Mostly mechanism / observational4 studies
Therapeutic & clinical
Mostly mechanism / observational3 studies
InflammationModest reduction in joint pain and stiffness · 8-12 weeks
Too few graded studies1 study
By the numbers
Pulled from 25 studies with measurable effects
Likely real effects
50%
across studies
People studied
73k
typical study: 166 people
Strongest designs
30
18 pooled, 12 randomised
Showed benefit
64%
7/11 studies
How long studies ran
1–3 months
1
3+ months
5
Populations Studied
Patients with osteoarthritis5
Patients with knee osteoarthritis5
Knee OA patients4
Patients with hand osteoarthritis1
Active research area
24 studies in the last 5 years · Latest meta-analysis: 2025
200620162026
1Safety of anti-osteoarthritis medicationsSystematic ReviewCited 6×n=22,938 · very large study2025
This SR confirms previous evidence on the safety of anti-OA medications from meta-analyses of phase 3 RCTs.
Honvo G et al. · Drugs (2025)
This SR confirms previous evidence on the safety of anti-OA medications from meta-analyses of phase 3 RCTs.
Beyond the evidence here reported, the limitations of this research highlight the urgent need of a reporting guideline for post-marketing safety surveillance studies.
Importantly, real-life safety surveillance of anti-OA medications should be strengthened with large cohort studies with control groups, and results should be disaggregated by disease populations for drugs common to several conditions.
3Pain reduction in hand osteoarthritisMeta-Analysisn=3,965 · very large study2024
In summary, GCSB-5 and CRx-102 exhibit efficacy in alleviating pain and stiffness in HOA, respectively.
Wu R et al. · PloS one (2024)
No clear effect
← WorseNo effectBetter →
GCSB-5, a specific herbal complex that mainly regulate pain in hand osteoarthritis, showed the greatest reduction in pain [WMD = -13.00, 95% CI (-26.69, 0.69)].
CRx-102, s specific medication characterized by its significant effect for relieving joint stiffness symptoms, remarkably mitigated stiffness [WMD = -7.50, 95% CI (-8.90, -6.10)].
Chondroitin sulfate displayed the highest incidence of adverse events [RR = 0.26, 95% CI (0.06, 1.22)].
Our study confirmed that the combination of glucosamine and chondroitin is effective and superior to other treatments in knee osteoarthritis to a certain extent.
Meng Z et al. · Archives of orthopaedic and trauma surgery (2023)
Our study confirmed that the combination of glucosamine and chondroitin is effective and superior to other treatments in knee osteoarthritis to a certain extent.
It is worthwhile to popularize and apply the combination in KOA treatment considering the point of effect, tolerability and economic costs.
Additionally, regarding the limited number of studies and uneven trial quality, more high-quality trials are required to investigate the accurate clinical advantages of the combination.
5Efficacy for osteoarthritis and joint painSystematic ReviewCited 1×n=146 · medium study2025
Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain.
Baden KER et al. · Nutrients (2025)
Huge benefit
← WorseNo effectBetter →
Of the 2013 articles screened, 146 studies were included in our review, with nearly 60% being randomized controlled trials and most conducted in Europe, Asia, or the U.S.
Most studies focused on osteoarthritis and joint pain, with over 90% of efficacy studies reporting positive outcomes and most safety studies indicating minimal or no adverse effects.
Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain.
6Meta-AnalysisCited 38×n=16,427 · very large study2015
The present study provided evidence for the symptomatic efficacy of glucosamine plus chondroitin in the treatment of knee OA.
Zeng C et al. · Scientific reports (2015)
All treatment options showed clinically significant improvement from baseline pain, but only glucosamine plus chondroitin showed clinically significant improvement from baseline function.
In terms of the structure-modifying effect, both glucosamine alone and chondroitin alone achieved a statistically significant reduction in joint space narrowing.
The present study provided evidence for the symptomatic efficacy of glucosamine plus chondroitin in the treatment of knee OA.
8Effectiveness and safety of SYSADOAs for knee osteoarthritisMeta-AnalysisCited 2×2025
Level of Evidence: Therapeutic Level II.
Park YB et al. · Medicina (Kaunas, Lithuania) (2025)
Regarding the safety profile, the risk ratios did not differ significantly between the treatment and control groups, including the placebo and non-placebo subgroups.
Conclusions: Glucosamine, chondroitin, and SKCPT/SKI306X improved the pain and function and were non-inferior to pharmacologic drugs for up to 12 months.
These findings support the clinical use of these SYSADOAs to treat knee OA.
10Cancer prevention with glucosamine and chondroitinMeta-AnalysisCited 2×2023
Moreover, NSAIDs use may have a synergistic protective effect.
Liu B et al. · Nutrition and cancer (2023)
Barely noticeable benefit
← WorseNo effectBetter →
The odds ratio (OR), corresponding to the 95% confidence interval (95% CI), was used to assess the association between chondroitin and/or glucosamine intake and cancer risk.
Overall, chondroitin and/or glucosamine intake was associated with a lower risk of colorectal cancer (OR = 0.91, 95% CI, 0.87-0.94) and lung cancer (OR = 0.84, 95% CI, 0.79-0.89).
Subgroup analysis supported the protective effect of different SYSADOAs (chondroitin and/or glucosamine) intake.
12Joint space narrowingMeta-AnalysisCited 227×n=37 · small study2018
In this systematic review and network meta-analysis of studies of patients with knee osteoarthritis and at least 12 months of follow-up, there was uncertainty around the estimates of effect size for change in pain for all comparisons with placebo.
Gregori D et al. · JAMA (2018)
Noticeable benefit
← WorseNo effectBetter →
Associations with improvement in joint space narrowing were found for glucosamine sulfate (SMD, -0.42 [95% CrI, -0.65 to -0.19]), chondroitin sulfate (SMD, -0.20 [95% CrI, -0.31 to -0.07]), and strontium ranelate (SMD, -0.20 [95% CrI, -0.36 to -0.05]).
In this systematic review and network meta-analysis of studies of patients with knee osteoarthritis and at least 12 months of follow-up, there was uncertainty around the estimates of effect size for change in pain for all comparisons with placebo.
Larger RCTs are needed to resolve the uncertainty around efficacy of medications for knee osteoarthritis.
13Pain improvement in osteoarthritisMeta-AnalysisCited 1×n=50 · small study2017
We concluded it is not clear whether the use of chondroitin sulfate leads to an improvement in pain or functionality in osteoarthritis because the certainty of the evidence is very low.
Rojas-Briones V et al. · Medwave (2017)
To answer this question we searched in Epistemonikos database, which is maintained by screening multiple information sources.
We identified 13 systematic reviews including 50 randomized trials overall.
We extracted data, conducted a meta-analysis and generated a summary of findings table using the GRADE approach.
The overall analysis including all trials showed that supplements provided moderate and clinically meaningful treatment effects on pain and function in patients with hand, hip or knee osteoarthritis at short term, although the quality of evidence was very low.
Liu X et al. · British journal of sports medicine (2018)
Another six (undenatured type II collagen, avocado soybean unsaponifiables, methylsulfonylmethane, diacerein, glucosamine and chondroitin) revealed statistically significant improvements on pain, but were of unclear clinical importance.
Chondroitin demonstrated statistically significant, but not clinically important structural improvement (effect size -0.30, -0.42 to -0.17).
The overall analysis including all trials showed that supplements provided moderate and clinically meaningful treatment effects on pain and function in patients with hand, hip or knee osteoarthritis at short term, although the quality of evidence was very low.
16Safety of symptomatic slow-acting drugs for osteoarthritisMeta-AnalysisCited 55×n=25 · very small study2019
GS and CS can be considered safe treatments for patients with OA.
Honvo G et al. · Drugs & aging (2019)
Huge harm
← WorseNo effectBetter →
In studies that allowed concomitant OA medications, diacerein was associated with significantly more dermatological disorders (OR 2.47; 95% CI 1.42-4.31; I2 = 0%) and more dropouts due to AEs (OR 3.18; 95% CI 1.85-5.47; I2 = 13.4%) than was placebo.
No significant increase in serious or severe AEs was found with diacerein versus placebo.
GS and CS can be considered safe treatments for patients with OA.
Given the effectiveness of these symptomatic slow-acting drugs, oral chondroitin is more effective than placebo on relieving pain and improving physical function.
Zhu X et al. · Journal of orthopaedic surgery and research (2018)
Given the effectiveness of these symptomatic slow-acting drugs, oral chondroitin is more effective than placebo on relieving pain and improving physical function.
Glucosamine showed effect on stiffness outcome.
Regarding on the limited number of combination therapy, further studies need to investigate the accurate effectiveness.
19Gastrointestinal complicationsSystematic ReviewCited 44×n=20 · very small study2018
Careful consideration should be given to medical management taking into account known co-morbidities.
Aweid O et al. · Journal of orthopaedic surgery (Hong Kong) (2018)
Huge harm
← WorseNo effectBetter →
Highest gastrointestinal complications were reported for diclofenac (odds ratio (OR) = 4.77 (3.94, 5.76)) and lowest for total knee replacement (HR = 0.6 (0.49, 0.75)).
Ibuprofen had the highest renal complications (OR = 2.32 (1.45, 3.71)), whereas celecoxib had the highest cardiovascular risk (OR = 2.26 (1, 5.1)) and lowest was for tramadol (RR = 1.1 (0.87, 1.4)).
Results show that medical management of hip and knee OA, particularly with non-steroidal anti-inflammatory drugs, may carry higher mortality compared to surgery.
Further studies are needed to evaluate the effect of glucosamine on knee function and joint preservation, as well as to evaluate the combined effect with other components, such as chondroitin.
Ogata T et al. · Clinical rheumatology (2018)
A newly established knee OA scale, the Japanese Knee Osteoarthritis Measure (JKOM), is commonly used in Japan.
Although the number of subjects was small, the JKOM meta-analysis indicated that glucosamine is superior to a placebo in alleviating knee OA symptoms.
Given this, we concluded that glucosamine has the potential to alleviate knee OA pain.